Coiled Therapeutics has enrolled six patients into two dosing groups testing a reformulated version of its cancer drug AO-252, designed to better cross the brain and block the cancer-driving protein TACC3. The new lipid-based softgel aims to provide more consistent absorption compared to the original tablet, which showed variable results in earlier trials. The company plans to dose up to 30 patients by the end of 2026 and expects initial safety and pharmacokinetic data by year-end, progressing toward larger studies in ovarian and prostate cancer. This reformulation reduces risk in their dose-escalation strategy and keeps development on track.
Coiled Therapeutics' cancer drug reformulation advances as of September 21, 2026. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 21, 2026 13:41 WIB: out of 92 priced US health stocks, 49 rose and 41 fell. Notable movers include Teladoc Health Inc (TDOC) at USD 6.24 with a -2.95% change and a typical hold time of 39 days, Baxter International Inc (BAX) at USD 22.90 with a -2.68% change and a typical hold time of 72 days, and Summit Therapeutics Inc (SMMT) at USD 18.29 with a +2.46% change and a typical hold time of 18 days.
Prismo Metals completed its 2026 surface reconnaissance at the Silver King project in Arizona, revealing an alteration system over 2 km wide with classic porphyry copper zoning. The findings include expanded potassic alteration, phyllic overprinting,...
Iofina PLC expects to produce a record volume of iodine in 2026, with output forecasted between 460 and 485 metric tonnes in the second half of the year. The company reported a sharp rise in profitability for the first half, with adjusted core earnin...
Accsys Technologies Plc forecasts full-year adjusted EBITDA between €21 million and €23 million, surpassing last year's results despite a 6% revenue decline to €56.9 million in the first five months. Sales volumes dropped 11%, impacted by distributor...
Chevron Corporation is capitalizing on Middle East supply disruptions to deliver strong earnings and cash flow, benefiting from high oil prices and operational efficiencies. The company’s limited direct exposure to the region has minimized physical r...
XRP has bounced back above $1.40 following a recovery from lows around $1.24–$1.26. Major holders accumulated about 1.54 billion XRP tokens worth approximately $2.2 billion in just 96 hours, signaling strong whale interest. Additionally, around 1.6 b...
